Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis
In conclusion, this study reveals a novel mechanism by which lidocaine inhibits HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis, highlighting a potential therapeutic avenue for HER2-positive breast cancer.
Authors
- Chengqi Deng
- Nan Hu (ORCID: https://orcid.org/0000-0002-7032-0558)
- Yunfei Sun (ORCID: https://orcid.org/0009-0005-5564-6305)
- Xuan Zhang (ORCID: https://orcid.org/0000-0003-0494-7691)
- Bo Liu (ORCID: https://orcid.org/0000-0003-4526-714X)
- Yiqing Yin
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Second Hospital of Tianjin Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1007/s12672-025-04194-4
- Citations
- 1
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 1.47